Direct oral anticoagulant use and risk of severe COVID‐19

BACKGROUND: Hypercoagulability and thromboembolism are prominent features of severe COVID‐19, and ongoing anticoagulant use might be protective. METHODS: We conducted a nationwide register‐based cohort study in Sweden, February through May, 2020, to assess whether ongoing direct oral anticoagulant (...

Descripción completa

Detalles Bibliográficos
Autores principales: Flam, B., Wintzell, V., Ludvigsson, J. F., Mårtensson, J., Pasternak, B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7753564/
https://www.ncbi.nlm.nih.gov/pubmed/33258156
http://dx.doi.org/10.1111/joim.13205

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7753564/
https://www.ncbi.nlm.nih.gov/pubmed/33258156
http://dx.doi.org/10.1111/joim.13205

Ejemplares similares